Inborn errors of pyrimidine metabolism: clinical update and therapy

Journal of Inherited Metabolic Disease

Volumn 37, Issue 5, 2014, Pages 687-698

  Balasubramaniam, Shanti ^a,b   Duley, John A ^c   Christodoulou, John ^d,e  

^a PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PYRIMIDINE DERIVATIVE;

GENETICS; HUMAN; METABOLISM; PURINE-PYRIMIDINE METABOLISM, INBORN ERRORS;

HUMANS; PURINE-PYRIMIDINE METABOLISM, INBORN ERRORS; PYRIMIDINES;

EID: 84929991543     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-014-9742-3     Document Type: Review

References (68)

1. Bailey CJ (2009) Orotic aciduria and uridine monophosphate synthase: a reappraisal. J Inherit Metab Dis 32(Suppl 1):S227–S233
2. Bax BE, Bain MD, Scarpelli M, Filosto M, Tonin P, Moran N (2013) Clinical and biochemical improvements in a patient with MNGIE following enzyme replacement. Neurology 81(14):1269–1271
3. Berg M, Tymoczko JL, Stryer L (2002) Biosynthesis of nucleotides. In: Berg M, Tymoczko JL, Stryer L (eds) Biochemistry. Freeman, New York, pp 602–626
4. Besley GTN, Walter JH, Fairbanks LD et al (2000) Hereditary orotic aciduria without megaloblastic anaemia. J Inherit Metab Dis 23(Suppl 1):194
5. Bushdid PB, Brantley DM, Yull FE (1998) Inhibition of NF-κB activity results in disruption of the apical ectodermal ridge and aberrant limb morphogenesis. Nature 392:615–618
6. Cameron JS, Moro F, Simmonds HA (1993) Gout, uric acid and purine metabolism in paediatric nephrology. Pediatr Nephrol 7:105–118
7. Caudle KE, Thorn CF, Klein TE, et al (2013) Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther 94:640–645
8. Chiang C, Litingtung Y, Harris MP et al (2001) Manifestation of the limb prepattern: limb development in the absence of sonic hedgehog function. Dev Biol 236:421–435
9. Chiarelli LR, Fermo E, Zanella A et al (2006) Hereditary erythrocyte pyrimidine 5′-nucleotidase deficiency: a biochemical, genetic and clinical overview. Hematol 11:67–72
10. Corson LB, Yamanaka Y, Lai K, Rossant J (2003) Spatial and temporal patterns of ERK signaling during mouse embryogenesis. Development 130:4527–4537
11. Dervieux T, Furst D, Lein DO et al (2004) Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 50:2766–2774
12. DiPaolo A, Chu E (2004) The role of thymidylate synthase as a molecular biomarker. Clin Cancer Res 10:411–412
13. Duran M, Dorland L, Meuleman EE, Allers P, Berger R (1997) Inherited defects of purine and pyrimidine metabolism: laboratory methods for diagnosis. J Inherit Metab Dis 20:227–236
14. Fairbanks LD, Marinaki AM, Carrey EA, Hammans SR, Duley JA (2002) Deoxyuridine accumulation in urine in thymidine phosphorylase deficiency (MNGIE). J Inherit Metab Dis 25(7):603–604
15. Filosto M, Scarpelli M, Tonin P et al (2012) Course and management of allogeneic stem cell transplantation in patients with mitochondrial neurogastrointestinal encephalomyopathy. J Neurol 259:2699–2706
16. Fox RM, O’Sullivan WJ, Firkin BG (1969) Orotic aciduria: differing enzyme patterns. Am J Med 47:332–336
17. Fox RM, Wood MH, Royse-Smith D, O_Sullivan WJ (1973) Hereditary orotic aciduria: types I and II. Am J Med 55:791–798
18. Fukushima R, Kanamori S, Hirashiba M et al (2009) Inhibiting the teratogenicity of the immunosuppressant leflunomide in mice by supplementation of exogenous uridine. Toxicol Sci 108:419–426
19. Grabar PB, Rozman B, Logar D, Praprotnik S, Dolzan V (2009) Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis. Ann Rheum Dis 68:1367–1368
20. Halter J, Schüpbach WM, Casali C et al (2011) Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a consensus conference proposal for a standardized approach. Bone Marrow Transplant 46(3):330–337
21. Hartmann S, Okun JG, Schmidt C et al (2006) Comprehensive detection of disorders of purine and pyrimidine metabolism by HPLC with electrospray ionization tandem mass spectrometry. Clin Chem 52(6):1127–1137
22. Hirano M, Marti R, Casali C et al (2006) Allogeneic stem cell transplantation corrects biochemical derangements in MNGIE. Neurology 67:1458–1460
23. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K (1995) Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 20:191–197
24. Imose M, Nagaki M, Kimura K et al (2004) Lefunomide protects from T-cell–mediated liver injury in mice through inhibition of nuclear factor κB. Hepatology 40:1160–1169
25. Jankowski V, Tölle M, Vanholder R et al (2005) Uridine adenosine tetraphosphate: a novel endothelium-derived vasoconstrictive factor. Nat Med 11:223–227
26. Jurecka A, Zikanova M, Tylki-Szymanska A et al (2008) Clinical, biochemical and molecular findings in seven Polish patients with adenylosuccinate lyase deficiency. Mol Genet Metab 94:435–442
27. Kumagai K, Hiyama K, Oyama T, Maeda H, Kohno N (2003) Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med 11:593–600
28. Lara MC, Weiss B, Illa I et al (2006) Infusion of platelets transiently reduces nucleoside overload in MNGIE. Neurology 67:1461–1463
29. Loeffler M, Zameitat E (2004) Pyrimidine biosynthesis. Encycl Biol Chem 3:600–605
30. Mahdaviani SA, Hirbod-Mobarakeh A, Wang N et al (2012) Novel mutation of the activation-induced cytidine deaminase gene in a Tajik family: special review on hyper-immunoglobulin M syndrome. Expert Rev Clin Immunol 8(6):539–546
31. Mancuso M, Salviati L, Sacconi S et al (2002) Mitochondrial DNA depletion: mutations in thymidine kinase gene with myopathy and SMA. Neurology 59:1197–1202
32. Marti R, Spinazzola A, Tadesse S, Nishino I, Nishigaki Y, Hirano M (2004) Definitive diagnosis of mitochondrial neurogastrointestinal encephalomyopathy by biochemical assays. Clin Chem 50:120–124
33. Millington D (2003) Tandem mass spectrometry in clinical diagnosis. In: Blau N, Duran M, Blaskovics M, Gibson M (eds) Physician’s guide to the laboratory diagnosis of metabolic diseases. Springer-Verlag, Berlin, pp 57–76
34. Najarian T, Traut TW (2000) Nifedipine and nimodipine competitively inhibit uridine kinase and orotidine-phosphate decarboxylase: theoretical relevance to poor outcome in stroke. Neurorehabil Neural Repair 14:237–241
35. Nakajima Y, Meijer J, Dobritzsch D et al (2014) Clinical, biochemical and molecular analysis of 13 Japanese patients with β-ureidopropionase deficiency demonstrates high prevalence of the p.977G>A (p.R326Q) mutation. J Inherit Metab Dis
36. Ng SB, Buckingham KJ, Lee C et al (2010) Exome sequencing identifies the cause of a mendelian disorder. Nat Genet 42:30–35
37. Nishino I, Spinazzola A, Papadimitriou A et al (2000) Mitochondrial neurogastrointestinal encephalomyopathy: an autosomal recessive disorder due to thymidine phosphorylase mutations. Ann Neurol 47:792–800
38. Oskoui M, Davidzon G, Pascual J et al (2006) Clinical spectrum of mitochondrial DNA depletion due to mutations in the thymidine kinase 2 gene. Arch Neurol 63:1122–1126
39. Pawlik A, Herczynska M, Kurzawski M, Safranow K, Dziedziejko V, Drozdzik M (2009) The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide. Pharmacogenomics 10:303–309
40. Pontarin G, Ferraro P, Valentino ML, Hirano M, Reichard P, Bianchi V (2006) Mitochondrial DNA depletion and thymidine phosphate pool dynamics in a cellular model of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). J Biol Chem 281:22720–22728
41. Quartier P, Bustamante J, Sanal O et al (2004) Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to activation-induced cytidine deaminase deficiency. Clin Immunol 110(1):22–29
42. Rainger J, Bengani H, Campbell L et al (2012) Miller syndrome (Genee-Wiedemann syndrome) represents a clinically and biochemically distinct subgroup of postaxial acrofacial dysostosis associated with partial deficiency of DHODH. Hum Mol Genet 21(18):3969–3983
43. Rees DC, Duley JA, Simmonds HA et al (1996) Interaction of haemoglobin E and pyrimidine 5′-nucleotidase deficiency. Blood 88:2761–2767
44. Rees DC, Duley JA, Marinaki AM (2003) Pyrimidine 5′ nucleotidase deficiency. Br J Haematol 120(3):375–383
45. Revy P, Muto T, Levy Y et al (2000) Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the hyper-IgM syndrome (HIGM2). Cell 102:565–575
46. Saada A, Shaag A, Mandel H et al (2001) Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy. Nat Genet 29:342–344
47. Schweitzer-Krantz S, van Kuilenburg ABP, van Gennip AH, Lehnert W (2002) Dihydropyrimidine dehydrogenase deficiency and arthrogryposis multiplex congenita: clinical improvement under substitution of β-alanine and β-aminoisobutyric acid. J Inherit Metab Dis 25(Suppl 1):155
48. Simmonds HA, van Gennip AH (2003) Purine and pyrimidine disorders. In: Blau N, Duran M, Blaskovics M, Gibron KM (eds) Physician’s guide to the laboratory diagnosis of metabolic diseases. Springer, Berlin, pp 445–465
49. Simmonds HA, Duley JA, Fairbanks LD, McBride MB (1997) When to investigate for purine and pyrimidine disorders. Introduction and review of clinical and laboratory indications. J Inherit Metab Dis 20:214–226
50. Smith LH Jr, Lotz M (1963) Studies on congenital orotic aciduria: comparison of orotic acid metabolism in micro-organisms. J Lab Clin Med 61:211
51. Spinazzola A, Marti R, Nishino I et al (2002) Altered thymidine metabolism due to defects of thymidine phosphorylase. J Biol Chem 277:4128–4133
52. Thomas HR, Ezzeldin HH, Guarcello V, Mattison LK, Fridley BL, Diasio RB (2008) Genetic regulation of beta-ureidopropionase and its possible implication in altered uracil catabolism. Pharmacogenet Genomics 18:25–35
53. Torres-Torronteras J, Gómez A, Eixarch H et al (2011) Hematopoietic gene therapy restores thymidine phosphorylase activity in a cell culture and a murine model of MNGIE. Gene Ther 18:795–806
54. Tyynismaa H, Sun R, Ahola-Erkkilä S et al (2012) Thymidine kinase 2 mutations in autosomal recessive progressive external ophthalmoplegia with multiple mitochondrial DNA deletions. Hum Mol Genet 21(1):66–75
55. van den Berghe G, Vincent MF, Marie S (2012) Disorders of purine and pyrimidine metabolism. In: Saudubray JM, van der Berghe G (eds) Walter J inborn metabolic diseases: diagnosis and treatment, 5th edn. Springer, Berlin, pp 500–518
56. van Gennip AH (1999) Defects in metabolism of purines and pyrimidines. Ned Tijdsch Klin Chem 24:171–175
57. van Gennip A, van Kuilenburg AB (2000) Defects of pyrimidine degradation: clinical, molecular and diagnostic aspects. Adv Exp Med Biol 486:233–241
58. van Kuilenburg AB (2004) Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40(7):939–950
59. van Kuilenburg ABP, Vreken P, Abeling NG et al (1999) Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet 104(1):1–9
60. van Kuilenburg ABP, Meinsma R, Zonnenberg BA et al (2003) Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity. Clin Cancer Res 9:4363–4367
61. van Kuilenburg AB, Stroomer AE, van Lenthe H, Abeling NG, Van Gennip AH (2004) New insights in dihydropyrimidine dehydrogenase deficiency: a pivotal role for beta-aminoisobutyric acid? Biochem J 379(1):119–124
62. van Kuilenburg ABP, Meijer J, Mul AN et al (2009) Analysis of severely affected patients with dihydropyrimidine dehydrogenase deficiency reveals large intragenic rearrangements of DPYD and a de novo interstitial deletion del(1)(p13.3p21.3). Hum Genet 125:581–590
63. van Kuilenburg AB, Dobritzsch D, Meijer J et al (2010) Dihydropyrimidinase deficiency: phenotype, genotype and structural consequences in 17 patients. Biochim Biophys Acta 1802(7–8):639–648
64. van Kuilenburg AB, Dobritzsch D, Meijer J et al (2012) ß-ureidopropionase deficiency: phenotype, genotype and protein structural consequences in 16 patients. Biochim Biophys Acta 1822(7):1096–1108
65. van Werkhoven MA, Duley JA, McGown I, Munce T, Freeman JL, Pitt JJ (2013) Early diagnosis of adenylosuccinate lyase deficiency using a high-throughput screening method and a trial of oral S-adenosyl-l-methionine as a treatment method. Dev Med Child Neurol 55(11):1060–1064
66. Wadman SK, Beemer FA, de Bree PK et al (1984) New defects of pyrimidine metabolism. Adv Exp Med Biol 165:109–114
67. Webster DR, Becroft DM, van Gennip A, Van Kuilenberg A (2001) Hereditary orotic aciduria and other disorders. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 2663–2702
68. Weisman MH, Furst DE, Park GS et al (2006) Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum 54:607–612